Compare Duke Energy Corp (DUK) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs Travere Therapeutics Inc. Common Stock — how do they compare? Duke Energy Corp trades at $120.33 (market cap $92.15B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Duke Energy Corp is far larger — about 18.9× Travere Therapeutics Inc. Common Stock's market cap, and Duke Energy Corp pays a 3.67% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 75 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| DUK | TVTX | |
|---|---|---|
Market Cap | $92.15B | $4.88B |
Volume | 3,498,824 | 1,668,577 |
Sector | Utilities | Health |
52-Week High | $133.46 | $67.52 |
52-Week Low | $113.23 | $26.79 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $184.66B | $5.01B |
Dividend Yield | 3.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $119.64, up 1.66% on the day, with a bullish technical signal despite some overbought RSI readings. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue and net income have grown steadily, reaching $32.24B and $4.97B in 2025, respectively, while maintaining strong profitability margins. Recent news highlights dividend declarations and data center growth opportunities.
The outlook for DUK is positive, supported by consistent earnings beats, a solid dividend yield, and strategic positioning in data center contracts. Risks include high debt levels, rising interest rates impacting utility stocks, and execution challenges in capital-intensive projects. Analyst consensus leans hold with a $131.50 price target, suggesting moderate upside from current levels.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
